Skip to content

TAGline 2004

2004 issues (December, October, September, August, July, June, May, April, March, February, January) of TAGline
Read more

ICAAC Roundup, 2004

The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) is the annual meeting of the American Society for Microbiology. In 2004, it happened in Washington DC from 30 Oct to 2 Nov. Some new drugs were presented along with data…

Read more

Brand-name FDCs and PEPFAR, 2004

September 2004 By Rob Camp In January 2003, W announced PEPFAR, The President's Emergency Plan For AIDS Relief, pledging 15 billion dollars of funding over 5 years, to provide testing and treatment in 15 countries affected by HIV/AIDS. Critique of…

Read more

Epzicom Brand Abacavir-Lamivudine QD

The Difference Between Drugs and New Drugs By Rob Camp August 2004 FDA announced approvals in early August of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents for the treatment of HIV-1 infection. FDCs are…

Read more

Two Out of Three Ain’t Bad

In early August, FDA announced approvals of two fixed-dose combination (FDC) antiretroviral drug products for use with other antiretroviral agents in the treatment of HIV-1 infection: GlaxoSmithKline's Epzicom® (abacavir/lamivudine) and Gilead Sciences, Inc.'s Truvada® (tenofovir disoproxil/emtricitabine).
Read more

NIH Hearing on Norvir 400% Price Increase, 2004

By Rob Camp Edited by Jen Curry AIDS Treatment Activists Coalition (ATAC) On Tuesday, May 25, 2004, the National Institutes of Health (NIH) hosted a public meeting to seek comment from invited individuals, organizations, and other stakeholders on the use…

Read more
Back To Top